Loading clinical trials...

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Generalised Anxiety Disorder

NCT00389064•AstraZeneca

View on ClinicalTrials.gov

Summary

The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder. PLEASE NOTE: Seroquel SR and Seroquel extended release(XR) refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Eligibility

Age

66 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female patients, 66 years or older, with a documented clinical diagnosis of Generalised Anxiety Disorder (GAD).
•Absence of current episode of major depression.

Exclusion Criteria

•The presence of dementia or other mental disorder than GAD.
•Serious suicidal risk, uncontrolled hypertension, substance or alcohol abuse.
•A current diagnosis of cancer or current or past diagnosis of stroke.

Locations (43)

Research Site

Fort Myers, Florida, United States

Research Site

Gainsville, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Sarasota, Florida, United States

Research Site

Roswell, Georgia, United States

Research Site

Boston, Massachusetts, United States

Research Site

Brooklyn, New York, United States

Research Site

The Bronx, New York, United States

Research Site

Avon Lake, Ohio, United States

Research Site

Eugene, Oregon, United States

Key Dates

Start Date

September 1, 2006

Primary Completion Date

April 1, 2008

Completion Date

April 1, 2008

Last Updated

April 4, 2012

Enrollment

450

ACTUAL participants

Conditions

Anxiety Disorders

Interventions

Quetiapine XR

DRUG

Placebo

DRUG

In Vivo Exposure vs. Videochat-Based Vicarious Exposure

NCT07432945

AnxietyAnxiety Disorders

View study

RECRUITINGNA

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders

NCT06661460

ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)Specific Phobia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 4, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

Inclusion Criteria

Exclusion Criteria

In Vivo Exposure vs. Videochat-Based Vicarious Exposure

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders

Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention

Investigating Neural Response Variability as a Single-patient Predictor of Successful CBT in Clinical Psychiatry

The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation